|Bid||0.00 x 800|
|Ask||0.00 x 1200|
|Day's range||47.20 - 49.20|
|52-week range||10.00 - 51.05|
|Beta (5Y monthly)||2.67|
|PE ratio (TTM)||N/A|
|Earnings date||09 Feb 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||13 Mar 2000|
|1y target est||51.44|
Anthem's (ANTM) fourth-quarter results benefit from higher revenues stemming from robust Medicaid and Medicare businesses, partly offset by higher costs.
Per Boston Scientific's (BSX) October update, it has started to see strong region-wise recovery.
Thermo Fisher's (TMO) Life-Science Solutions and Specialty Diagnostics segments are expected to have contributed, banking on COVID-19-led growing healthcare needs.